COLY-MYCIN M (colistimethate sodium)
COLY-MYCIN M is indicated for the treatment of Bacterial Infections.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1970-06-04
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
COLY-MYCIN M Approval History
What COLY-MYCIN M Treats
1 indicationsCOLY-MYCIN M is approved for 1 conditions since its original approval in 1970. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Bacterial Infections
COLY-MYCIN M Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to COLY-MYCIN M
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06488794 ColiPed | FThabet | Ph 2, Ph 3 | not yet recruiting | Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia |
| NCT06893835 MDRS | Multidrug resistance | Ph 4 | active not recruiting | Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline |
| NCT03397914 | 103 | Ph 4 | completed | Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections |
| NCT01863719 | 10-0082 HHSN272201500007I | Ph 1 | terminated | Aerosolized and Intravenous Colistin in Healthy Adults |
| NCT02966457 DEHAM | HEM-3_1 | Ph 4 | completed | A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) |
| NCT01449838 | 114490 | Ph 1 | completed | Phase I Study of Colistin Methanesulfonate Sodium |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
COLY-MYCIN M FDA Label Details
Indications & Usage
FDA Label (PDF)COLY-MYCIN M is indicated for the treatment of Bacterial Infections.
Track COLY-MYCIN M with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment